Wednesday, June 29, 2022

ITUS Corp (NASDAQ:ITUS) Up Big On Patent News

ITUS Corp (NASDAQ:ITUS) is seeing a sizeable jump again today on what could be legitimately exciting news for cancer research. ITUS, which is up 25% on the week, received a patent for its cancer detection technology and the market is seemingly liking what it sees.
Dr. Kumar, CEO of ITUS, stated: “This is the first patent to issue of several patents that we expect to issue garnering protection of our cancer detection technology. The claims of this patent were allowed in May of 2017, and now we have received the official issuance notification and patent number. We currently have one other key patent application pending at the USPTO and expect to file for additional patent protection as our research and development continues.”
 ITUS Corp (NASDAQ:ITUS) is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient’s immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Instead of seeking to alter or boost the body’s immune system and its ability to destroy cancer cells, the Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients, and in distinguishing the blood of healthy patients from the blood of cancer patients.
Find out when ITUS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.


Dr. Kumar added, “ITUS’s unique liquid biopsy approach utilizes flow cytometry to measure the presence and characteristics of certain circulating immune cells. We then use Artificial Intelligence to analyze the data in a manner that enables us to identify tumor bearing patients. The test utilizes a simple blood draw from the patient. To date, our technology has demonstrated its ability to identify 15 cancer types including breast, prostate, colon, lung, pancreatic, and others. Because we are measuring subtle changes in circulating immune cells, it is not surprising that our technology appears to work on multiple cancer types, and we expect the technology will eventually be able to identify all cancer types. ITUS is performing additional tests including the evaluation of benign conditions which may exist in patients but are not malignant tumors.”
Yesterday, after the announcement, ITUS’ shares closed up 85.51% on nearly 23 million shares traded. Trading volume yesterday was explosive for the stock compared to its average of just around 230,000 shares.
ITUS Corp (NASDAQ:ITUS) is seeing pronounced volume again today. This company needs to be in your crosshairs as this patent ripples across the market and the sector. ITUS has a $35.59M market cap along with 15.12M shares out. Something to keep in mind, this stock was worth more than $5 earlier this year and could easily return to that level. Sign-up for continuing coverage on shares of $ITUS stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: We hold no position in $ITUS, either long or short, and we have not been compensated for this article.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
3,368FollowersFollow
19,800SubscribersSubscribe

Latest Articles